RT Journal Article
T1 Addressing catheter lock therapy: Does heparin reduce the bioactivity of dalbavancin when together in solution during freezing?
A1 Díaz Navarro, Marta
A1 Hafian, Rama
A1 Pérez Granda, María Jesús
A1 Cercenado Mansilla, Emilia
A1 Muñoz García, Patricia Carmen
A1 Guembe, María
AB Introduction: The possible use of dalbavancin as a catheter lock solution was previously demonstrated by our study group. However, it was needed to assess whether heparin could affect dalbavancin bioactivity during freezing storage.Methods: We tested the bioactivity of a dalbavancin+heparin (DH) vs. dalbavancin (D) against Staphylococcal biofilms comparing DH median value of cfu counts and metabolic activity with that obtained for D before and during storage under freezing up to 6 months.Results: Despite there was a slight decrease in the median percentage reduction of metabolic activity at month 3 in Staphylococcus epidermidis between DH and D (97.6 vs. 100, p=0.037), considering the clinical criteria, no significant reduction in any of the variables tested was observed at the end of the experiment between D and DH solutions.Conclusion: The addition of heparin to a dalbavancin lock solution did not affect its bioactivity against staphylococcal biofilms irrespective of its preservation time under freezing.Keywords: Bioactividad; Bioactivity; Biofilms; Biopelículas; Congelación; Dalbavancin; Dalbavancina; Freezing; Heparin; Heparina; Lock therapy; Terapia de sellado.
PB Elsevier
SN 2529-993X
YR 2024
FD 2024-10
LK https://hdl.handle.net/20.500.14352/111245
UL https://hdl.handle.net/20.500.14352/111245
LA eng
NO Díaz-Navarro, M., Hafian, R., Pérez-Granda, M. J., Cercenado, E., Muñoz, P., & Guembe, M. (2024). Addressing catheter lock therapy: Does heparin reduce the bioactivity of dalbavancin when together in solution during freezing? Enfermedades Infecciosas y Microbiologia Clinica (English Ed.), 42(8), 435-438. https://doi.org/10.1016/j.eimce.2024.02.013
NO M. Guembe is supported by the Miguel Servet Program (ISCIII-MICINN, MS18/00008) of the Health Research Fund (FIS) of the Carlos III Health Institute (ISCIII), Madrid, Spain. M. Díaz-Navarro is supported by ISCIII (FI22/00022). The study was partially financed by grants from the ISCIII (PI21/00344), the Fundación Mutua Madrileña (FMM21/01), IiSGM (2022-PI-II-COOPTR-01), and the European Regional Development Fund (FEDER) “A way of making Europe”.
NO Ministerio de Ciencia e Innovación (España)
NO Instituto de Salud Carlos III (España)
NO Fundación Mutua Madrileña
NO Instituto de Investigación Sanitaria Gregorio Marañón
NO Unión Europea
DS Docta Complutense
RD 18 abr 2025